ClinicalTrials.gg
RecruitingNCT07384715Updated Nov 4, 2026

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

A Phase 1 interventional study of GEN3018 in R/R AML, R/R HR-MDS and Acute Myeloid Leukemia, sponsored by Genmab. Recruiting at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Genmab · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 27, 2026First site in Italy9 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 200 studies in Leukemia, Myeloid, Acute with a site in Spain — 35 open to participants now, 62 under way, 22 of them phase 3. Leukemia, Myeloid, Acute · Spain.

Planned enrollment
116th of 189
78 · median 120
Started
2026
with 6 others
Phase 1
46 of 200
6 open now
Primary completion
2029-10
later than 52 of 61 live
Registered
195th of 200
by date

Among the 200 studies in Leukemia, Myeloid, Acute with a site in Spain, this one is the 116th largest by planned enrollment of the 189 interventional ones that give a count, is one of 7 that started in 2026, is one of 46 in phase 1, reaches primary completion later than 52 of the 61 other live ones, and was the 195th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

35 of the 200 studies in Leukemia, Myeloid, Acute with a site in Spain are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies in Leukemia, Myeloid, Acute with a site in Spain, or all of them as a file.
02

Study summary

The drug that will be investigated in the trial is an antibody, GEN3018. Since this is the first trial of GEN3018 in humans, the main purpose is to evaluate safety. In addition to safety, the trial will determine the recommended GEN3018 dose(s) to be tested in a larger group of participants and assess preliminary anti-tumor activity of GEN3018. GEN3018 will be studied in refractory (resistant to treatment) or relapsed (disease has returned) acute myeloid leukemia (also known as R/R AML) and refractory or relapsed higher-risk myelodysplastic syndrome (also known as R/R HR-MDS). The trial consists of 2 parts:

Part 1 Dose Escalation will test increasing doses of GEN3018 to identify a safe dose level to be tested in the next part Part 2 Dose Refinement will further test the GEN3018 dose(s) determined from the Dose Escalation.

Up to 78 participants may be treated in this trial (up to 60 participants in Part 1; up to 18 participants in Part 2).

For an individual participant in the trial, the estimated treatment duration will be up to 1 year. Participation in the trial will require regular scheduled visits to the site. At site visits, there will be various tests (such as blood draws) to monitor whether the treatment is safe and effective. Participants will also be contacted every 3 months after treatment ends to monitor how they are doing.

All participants in the trial will receive active drug (ie, GEN3018); no one will be given placebo.

Read the detailed description

This is a FIH, Phase 1, open-label, multicenter trial in participants with R/R AML or R/R HR-MDS, to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary anti-tumor activity of GEN3018. The trial will be conducted in 2 parts: Dose Escalation (Part 1) and Dose Refinement (Part 2).

03

Conditions studied

  • R/R AML
  • R/R HR-MDS
  • Acute Myeloid Leukemia
  • Higher-Risk Myelodysplastic Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

All Participants:

  • Be at least 18 years of age at the time of signing form (ICF).
  • Participant's at screening is judged to be at least 3 months.
  • Must have fresh bone marrow samples collected at screening.
  • Bone marrow (BM) blasts ≥ 5% at screening.
  • (ECOG) performance status (PS) score of ≤ 2.
  • Has acceptable laboratory test results during the screening period

Participants with R/R AML:

  • AML, either de novo or secondary, and must have failed all conventional therapies.
  • Relapsed or refractory to at least one .

Participants with R/R HR-MDS:

  • Diagnosed with high- or very-high risk MDS according to International Prognostic Scoring System (IPSS-R) (score of > 4.5 ie, high or very high) or World Health Organization (WHO) 2022 classification (ie, MDS-IB1 or MDS-IB2).
  • Refractory or relapsed after hypomethylating agents (HMAs) (such as azacitidine or decitabine).

Key Exclusion Criteria:

All Participants:

  • Diagnosis of acute promyelocytic leukemia (APL).
  • Presence of extramedullary AML at screening.
  • Prior autologous or allogenic hematopoietic stem cell transplant () within 3 months prior to initiation of trial treatment.
  • Active .
  • History of severe immune-related adverse events.
  • Treatment with anti-cancer agent (eg, small molecule, antibody, chemotherapy, radiation therapy), or major surgery within 2 weeks prior to the first dose of GEN3018.

Other protocol-defined Inclusion and Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    GEN3018

    Participants will receive escalating doses of GEN3018 in Part 1 (Dose Escalation). In Part 2 (Dose Refinement), additional participants may be enrolled to evaluate the safety and preliminary efficacy data of the recommended Part 2 dose(s) as determined from the Part 1 Dose Escalation.

    Biological: GEN3018

Interventions

  • BiologicalGEN3018

    Intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants with Dose-limiting Toxicities (DLTs)

    Time frame: 28 days

  2. Parts 1 and 2: Number of Participants with Adverse Events (AEs)

    Time frame: Up to approximately 36 months

Secondary outcomes

  1. Parts 1 and 2: Maximum Concentration (Cmax) of GEN3018

    Time frame: Cycle 1 and 2 (each cycle is 28 days)

  2. Parts 1 and 2: Time to Cmax (tmax) of GEN3018

    Time frame: Cycle 1 and 2 (each cycle is 28 days)

  3. Parts 1 and 2: Predose Trough Concentration (Ctrough) of GEN3018

    Time frame: Cycle 1 and 2 (each cycle is 28 days)

  4. Parts 1 and 2: Area Under the Concentration-time Curve from Time 0 to Last Quantifiable Sample (AUClast) of GEN3018

    Time frame: Cycle 1 and 2 (each cycle is 28 days)

  5. Parts 1 and 2: Elimination Half-life (t1/2) of GEN3018

    Time frame: Cycle 1 and 2 (each cycle is 28 days)

  6. Parts 1 and 2: Clearance (CL) of GEN3018

    Time frame: Cycle 1 and 2 (each cycle is 28 days)

  7. Parts 1 and 2: Number of Participants with Anti-drug Antibodies (ADAs) Against GEN3018

    Time frame: Up to approximately 1 year

  8. Parts 1 and 2: ORR

    Time frame: Up to approximately 1 year

  9. Parts 1 and 2: Duration of Response (DOR)

    Time frame: Up to approximately 1 year

  10. Parts 1 and 2: Time to Response (TTR)

    Time frame: Up to approximately 1 year

07

Study locations

6 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2029, 44 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 44 months is close to that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 3, 2026
StartActual
Feb 16, 2026
Primary completionEst.
Oct 18, 2029
CompletionEst.
Apr 20, 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 6 sites removed — first site in Italy
Show 9 added (4 Spain, 3 Italy, 2 Denmark)
  • Aarhus Universitetshospital - Skejby · Aarhus, Denmark
  • Copenhagen Rigshospitalet · Copenhagen, Denmark
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • Hospital Clínic de Barcelona · Barcelona, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitari i Politècnic La Fe · Valencia, Spain
  • ASST Papa Giovanni XXIII · Bergamo, Italy
  • Istituto Clinico Humanitas · Milan, Italy
  • Azienda Ospedaliero Universitaria Pisana · Pisa, Italy
Show 6 removed
  • Aarhus Universitetshospital - Skejby · Aarhus, Denmark
  • Copenhagen Rigshospitalet · Copenhagen, Denmark
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • Hospital Clínic de Barcelona · Barcelona, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitari i Politècnic La Fe · Valencia, Spain
across 2 updates, Oct 6, 2026 – Oct 27, 2026
Secondary outcomes
1 edited, 1 time frame changed
What changed in the outcomes
  • EditedParts 1 and 2: Overall Response Rate (ORR)Time frame: Up to approximately 1 year
  • Time frameParts 1 and 2: Clearance (CL) of GEN3018Cycle1 and 2 (each cycle is 28 days) → Cycle 1 and 2 (each cycle is 28 days)
Oct 27, 2026
Show all 3 updates
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 27, 2026
    3 sites added — first site in Italy
    Show 3 added (3 Italy)
    • ASST Papa Giovanni XXIII · Bergamo, Italy
    • Istituto Clinico Humanitas · Milan, Italy
    • Azienda Ospedaliero Universitaria Pisana · Pisa, Italy
    Secondary outcomes 1 edited, 1 time frame changed
    What changed in the outcomes
    • EditedParts 1 and 2: Overall Response Rate (ORR)Time frame: Up to approximately 1 year
    • Time frameParts 1 and 2: Clearance (CL) of GEN3018Cycle1 and 2 (each cycle is 28 days) → Cycle 1 and 2 (each cycle is 28 days)
    + 1 other change: description
  3. Oct 6, 2026
    6 sites added, 6 sites removed
    Show 6 added (4 Spain, 2 Denmark)
    • Aarhus Universitetshospital - Skejby · Aarhus, Denmark
    • Copenhagen Rigshospitalet · Copenhagen, Denmark
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • Hospital Clínic de Barcelona · Barcelona, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitari i Politècnic La Fe · Valencia, Spain
    Show 6 removed
    • Aarhus Universitetshospital - Skejby · Aarhus, Denmark
    • Copenhagen Rigshospitalet · Copenhagen, Denmark
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • Hospital Clínic de Barcelona · Barcelona, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitari i Politècnic La Fe · Valencia, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07384715
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Feb 3, 2026
Start date
Feb 16, 2026
Primary completion
Oct 18, 2029 (estimated)
Completion
Apr 20, 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

Genmab Trial Information
Contact
clinicaltrials@genmab.com
+4570202728
Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion